drugset / Trial / NCT03774771
Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism
RandomizedSequentialDouble-blindTreatment
Summary
The primary objective was to assess the safety and tolerability of cinacalcet in adults with primary hyperparathyroidism (HPT) when administered as a single oral once daily doses for 6 consecutive weeks and twice daily for 15 consecutive days.
Timeline
- Start
- 1998-09-29
- Primary completion
- 1999-12-13
- Completion
- 1999-12-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cinacalcet | Other / unclassified | 50 mg | Oral |
| Subject | Cinacalcet | Other / unclassified | 75 mg | Oral |
| Subject | Cinacalcet | Other / unclassified | 100 mg | Oral |